Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 501–600 of 798
Nilsen, J., Aaen, K. H., Benjakul, S., Ruso‐Julve, F., Greiner, T. U., Bejan, D., Stensland, M., Singh, S. K., Schlothauer, T., Sandlie, I., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08249-8 · Cited by 21
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
“This turns active GIP (142) into inactive GIP (3-42) with little to no insulinotropic effect.”
BackgroundMorrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 19
Cao, N., Merchant, W., & Gautron, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-74000-8 · Cited by 22
Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
Giorgino, F., Leonardini, A., Natalicchio, A., & Laviola, L. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346698 · Cited by 18
Bremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20
“In vivo, GLP-1 is metabolized rapidly by the enzyme, dipeptidyl peptidase4 (DPP-4), leading to the formation of a truncated form, GLP-19–36amide (Deacon et al. 1995), which is inactive with respect to insulin secretion, but seems to share at least some of its vascular actions with intact GLP-1 (Ban et al.”
BackgroundSelf-citationMerkel, R., Moreno, A., Zhang, Y., Herman, R. J., Nathan, J. B., Zeb, S., Rahematpura, S., Stecyk, K. S., Milliken, B. T., Hayes, M. R., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.026 · Cited by 17
Gagnon, J., Mayne, J., Chen, A., Raymond, A., Woulfe, J., Mbikay, M., & Chrétien, M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.11.010 · Cited by 17
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
“Despite early encouraging results with intravenous infusion [9-11], native GLP-1 was determined to be an impractical therapeutic tool, due to its rapid extensive metabolism by dipeptidyl peptidase 4 (DPP-4) [12, 13].”
BackgroundOwji, A. A., Khoshdel, Z., Sanea, F., Panjehshahin, M. R., Fard, M. S., Smith, D. M., Coppock, H. A., Ghatei, M. A., & Bloom, S. R. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03379-0 · Cited by 18
Kapitza, C., Zdravkovic, M., Zijlstra, E., Segel, S., Heise, T., & Flint, A. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374474 · Cited by 21
“Endogenous GLP-1 has a short half-life attributable to rapid metabolism by dipeptidyl peptidase-IV (DPP-IV).(6,7) From human studies it has become clear that a continuous infusion of GLP-1 would be necessary to achieve satisfactory glycemic control.”
BackgroundAbdel‐Wahab, Y. H. A., O'Harte, F. P. M., Mooney, M. H., Conlon, J. M., & Flatt, P. R. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(99)00108-1 · Cited by 17
Kim, T. I., Lee, M., & Kim, S. W. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.072 · Cited by 18
“Two active forms of GLP-1 [20], GLP-1 (7–36) and GLP-1 (7–37) lose their two N-terminal amino acid residues and biological activity by action of DPPIV quickly in the body.”
BackgroundKalli, S. B., & Velmurugan, V. (2022) · Pharmacia · doi:10.3897/pharmacia.69.e95096 · Cited by 18
Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation
White, P. C., Shea, H. C., & de la Morena, M. T. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.09.001 · Cited by 19
Synthesis and characterization of ester‐based prodrugs of glucagon‐like peptide 1
De, A., & DiMarchi, R. D. (2010) · Biopolymers · doi:10.1002/bip.21418 · Cited by 18
The pathophysiologic role of incretins.
Freeman, J. S. (2007) · PubMed · Cited by 17
Nakaya, K., Kubota, N., Takamoto, I., Kubota, T., Katsuyama, H., Sato, H., Tokuyama, K., Hashimoto, S., Goto, M., Jomori, T., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.010 · Cited by 16
A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite
Albrechtsen, N. J. W., Asmar, A., Jensen, F. H., Toräng, S., Simonsen, L., Kuhre, R. E., Asmar, M., Veedfald, S., Plamboeck, A., Knop, F. K., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00005.2017 · Cited by 15
“This may seem reasonable given that GLP-1 9–36NH2 is the major circulating amidated GLP-1 isoform, at least in humans (7).”
BackgroundSelf-citationDay, S. M., Yang, W., Ewin, S. E., Zhou, X., & Ma, T. (2017) · Hippocampus · doi:10.1002/hipo.22795 · Cited by 19
Larsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 21
“However, both GLP-1 and GIP are rapidly degraded to apparently inactive metabolites by the enzyme dipeptidyl peptidase IV (DPPIV) [10, 11, 30, 41], although GIP seems less susceptible to degradation than GLP-1 [9, 10].”
BackgroundMethodSelf-citationZhang, J., Liu, S., Zhang, H., Li, Y., Wu, W., & Zhang, H. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.020 · Cited by 15
Nguyễn, T. D., Shingu, Y., Amorim, P., Schwarzer, M., & Doenst, T. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.018 · Cited by 18
“Once secreted into the blood, GLP-1 is rapidly degraded and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in low levels and thus insufficient biological activities [3].”
Alshambaty, K., Yagi, S. M. A., Elbashir, A. A., Schohn, H., Tzanova, T., Mohammed, I., Ak, G., Mahomoodally, M. F., Stefanucci, A., Mollica, A., et al. (2020) · South African Journal of Botany · doi:10.1016/j.sajb.2020.10.008 · Cited by 16
In Vivo Regeneration of Insulin-Producing β-Cells
Jun, H. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_27 · Cited by 16
Polymeric Gene Delivery for Diabetic Treatment
Kim, S. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.4.317 · Cited by 15
“The rapid initial degradation is due to the ubiquitously expressed enzyme, dipeptidyl peptidase IV (DPP-IV) [28], which cleaves off the 2 N-terminal amino acid residues.”
BackgroundInfluentialIncretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 18
“Endogenous GLP1 (and its synthetic peptide) has a plasma half-life of only 1 to 2 minutes [42] due to rapid metabolism by the ubiquitous, nonspecific enzyme dipeptidyl-peptidase 4 (DPP-4), which forms an inactive metabolite that is rapidly cleared by the kidneys [43], necessitating continuous infusion.”
BackgroundMedicinal Chemistry of Glucagon-Like Peptide Receptor Agonists
Jones, L. H., & Price, D. A. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00002-8 · Cited by 19
Wu, W., Sheng, K., Xu, X., Zhang, H., & Zhou, G. (2018) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2018.02.003 · Cited by 15
Review: DPP IV inhibitors - current evidence and future directions
Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 17
Modern, new pharmacotherapy for obesity. A gastrointestinal approach
Gaal, L. V., Mertens, I. L., Ballaux, D., & Verkade, H. J. (2004) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.09.001 · Cited by 15
E. Näslund, J. B. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520121133 · Cited by 15
1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors
Coppola, G. M., Zhang, Y. L., Schuster, H. F., Russell, M. E., & Hughes, T. E. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00286-9 · Cited by 15
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
“DPP-IV is also found soluble in plasma, where some GLP-1 degradation also occurs [125,141,142].”
BackgroundHepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
“Human studies on the insulinotropic action of GLP-1 were then rapidly conducted in United States of America and European countries [29 – 32].”
BackgroundA Peptidomics Strategy To Elucidate the Proteolytic Pathways That Inactivate Peptide Hormones
Tinoco, A. D., Kim, Y., Tagore, D. M., Wiwczar, J. M., Lane, W. S., Danial, N. N., & Saghatelian, A. (2011) · Biochemistry · doi:10.1021/bi2000033 · Cited by 16
Delivery of Peptides and Proteins via Long Acting Injections and Implants
Stevenson, C. L., Rhodes, C. A., & Prestrelski, S. J. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0554-2_20 · Cited by 14
Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare, K. J. (2010) · PubMed · Cited by 18
Kerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.021 · Cited by 15
Howard, J. W., Kay, R. G., Jones, B. J., Cegla, J., Tan, T., Bloom, S. R., & Creaser, C. S. (2017) · Bioanalysis · doi:10.4155/bio-2017-0021 · Cited by 14
Zhang, H., Song, B., Zhu, W., Liu, L., He, X., Wang, Z., An, K., Cao, W., Shi, J., & Wang, S. (2021) · Aging · doi:10.18632/aging.203351 · Cited by 14
“[60], several cells in the brain could also produce an amount of GLP-1 [19, 20].”
BackgroundMeurer, J. A., Colca, J. R., Burton, P. S., & Elhammer, Å. P. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90170-1 · Cited by 14
Pradeloux, S., Coulombe, K., Ouamba, A. J. K., Isenbrandt, A., Calon, F., Roy, D., & Soulet, D. (2024) · Nutrients · doi:10.3390/nu16193309 · Cited by 15
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 14
“Moreover, native GLP-1 is rapidly degraded in vivo by the enzyme dipeptidly peptidase (DPP) IV and cleared by the kidneys such that the halflife of GLP-1 is only a few minutes [56-60].”
BackgroundKaliora, A. C., Kanellos, P. T., Gioxari, A., & Karathanos, V. Τ. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.0123 · Cited by 15
“33 On the contrary, the study of Hoggard et al. 34 investigated the acute effect of a standardized bilberry extract on glucose metabolism and GIP and GLP-1 in diabetic patients and there was no difference in treatment for the iAUC for plasma GIP and GLP-1 or for any of the individual time points…”
Foley, J. E., & Åhrén, B. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.56 · Cited by 16
“In early 1995, it was reported that the inhibition of DPP-4 raised GLP1 levels in vitro.(6) Within weeks, Ed Villhauer went through the Sandoz chemical library and identified a molecule called valine pyrrolidide, an orally active DPP-4 inhibitor which had been identified by the Sandoz immunology group.”
BackgroundRichards, R. M., Scholz, I., Powers, C., Skach, W. R., & Früh, K. (2011) · Journal of Virology · doi:10.1128/jvi.05021-11 · Cited by 13
Albiglutide for the management of type 2 diabetes
Rendell, M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1419061 · Cited by 16
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes
Åhrén, B. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.08.001 · Cited by 18
Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1
Zhang, Z., Yang, S., Hong, D., Mao, J., & Li, K. (2004) · Protein Expression and Purification · doi:10.1016/j.pep.2004.03.014 · Cited by 16
Linnemann, A. K., & Davis, D. B. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12465 · Cited by 14
Updating the Role of α-Cell Preproglucagon products on GLP-1 receptor–mediated insulin secretion
Sandoval, D. (2020) · Diabetes · doi:10.2337/dbi19-0027 · Cited by 12
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Foley, J. E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00780 · Cited by 14
“The DPP-4 program was accelerated in 1995 after it was reported that DPP4 inhibition raised GLP-1 in vitro (3, 5).”
BackgroundWu, J., Cheng, A. S., Weimbs, T., Harris, P. C., Zhou, J. X., & Li, X. (2025) · The FASEB Journal · doi:10.1096/fj.202501605r · Cited by 15
Active glucagon-like peptide-1 (GLP-1): Storage of human plasma and stability over time
Marino, L. D., Griffo, E., Maione, S., & Mirabella, M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.05.011 · Cited by 12
“1%are added toheparinized [2] or EDTA [3] human plasma.”
BackgroundDas, A., Geetha, K. M., & Hazarika, I. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09927-y · Cited by 12
Esser, N., Mongovin, S. M., Parilla, J. H., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J., Akter, R., Hull, R. L., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00234.2021 · Cited by 14
Hou, J., Yan, R., Ding, D., Yang, L., Wang, C., Wu, Z., Yu, X., Li, W., & Li, M. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9427-1 · Cited by 14
“However, endogenous as well as exogenous GLP1 is rapidly metabolized by the endopeptidase dipeptidyl peptidase IV (DPP-IV), resulting in the formation of a metabolite, GLP-1 (9–36) amide (Deacon et al. 1995).”
BackgroundRebirth of the Incretin Concept: Its conception and early development
Marks, V. (2017) · Peptides · doi:10.1016/j.peptides.2017.08.002 · Cited by 12
Therapeutic potential of spinal GLP-1 receptor signaling
Zhang, D., & Lv, G. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.003 · Cited by 13
Kim, H. J., Kwak, W. Y., Min, J. P., Sung, S. Y., Kim, H. D., Kim, M.-K., Kim, H. S., Park, K. J., Son, M. H., Kim, S. H., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.019 · Cited by 13
Üçkaya, G., Delagrange, P., Chavanieu, A., Grassy, G., Berthault, M., Ktorza, A., Cerasi, E., Leibowitz, G., & Kaiser, Ν. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05818 · Cited by 12
“A major obstacle for the use of GLP-1 in vivo is its rapid degradation, primarily by dipeptidyl peptidase IV (Deacon et al. 1995).”
BackgroundThorstenson, A., Jacobsson, H., Onelöv, E., Holst, J. J., Hellström, P. M., & Kinn, A. (2006) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590600911217 · Cited by 12
“RIA for determination of the plasma concentration of GLP-1 was performed as previously described [13].”
MethodSelf-citationUse of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?
Mabilleau, G. (2014) · Endocrine · doi:10.1007/s12020-014-0461-1 · Cited by 12
“However, in the blood stream, GLP-1 is rapidly inactivated by the dipeptidyl peptidase-4 (DPP4) enzyme [2].”
BackgroundPreproglucagon Products and Their Respective Roles Regulating Insulin Secretion
Bethea, M. M., Bozadjieva-Kramer, N., & Sandoval, D. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab150 · Cited by 12
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“These facts in essence raise critical questions concerning an endocrine action of endogenous GLP-1 on the pancreatic beta cells except for situations when circulating GLP-1 levels are very high, as after bariatric surgery or after pharmacologic inhibition of DPP-IV.”
InfluentialGhazanfar, H., Kandhi, S. D., Nawaz, I., Javed, N., Abraham, M. C., FARAG, M. E., Mahasamudram, J., Patel, V. B., Altaf, F., & Patel, H. (2021) · Cureus · doi:10.7759/cureus.15141 · Cited by 14
“5-2 minutes due to its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) [22], liraglutide, on the other hand, is a long-acting (half-life: 13 hours) GLP-1 analog with 97% structural”
BackgroundInfluentialBlaslov, K., Bulum, T., Zibar, K., & Duvnjak, L. S. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12194 · Cited by 12
Incretin hormones and beta-cell mass expansion: what we know and what is missing?
Tortosa, F., & Dotta, F. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.795175 · Cited by 10
“Exenatide is the first GLP-1 receptor agonist approved in April 2005 for the treatment of T2DM.”
BackgroundInfluentialGrossman, S. S. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0101-4 · Cited by 11
“However, exenatide is more resistant to the activity of DPP-4 [18], a widely dispersed protease that rapidly cleaves native GLP-1 in vivo [22].”
Gao, Z., Tang, Y., Chen, J., Bai, R., Zhang, Q., Hou, Y., Lu, Y., & Bai, G. (2009) · Peptides · doi:10.1016/j.peptides.2009.07.020 · Cited by 14
“However, the benefits of GLP-1 as a therapeutic agent are limited by its short half-life, which is only 2–3 min because of its rapid degradation and inactivation under physiological conditions by dipeptidyl peptidase-IV (DPP-IV) [9].”
Chen, J., Bai, G., Yang‐Hartwich, Y., Geng, P., Cao, Y., & Zhu, Y. (2006) · Peptides · doi:10.1016/j.peptides.2006.12.012 · Cited by 13
Pharmacology of GLP-1-based therapies
Holst, J. J. (2008) · The British Journal of Diabetes · doi:10.1177/1474651408100523 · Cited by 12
Self-citationGLP-1: Target for a New Class of Antidiabetic Agents?
Edwards, C. M. B. (2004) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.97.6.270 · Cited by 12
Carr, R. D. (2016) · Diabetic Medicine · doi:10.1111/dme.13066 · Cited by 12
Schwanstecher, C., & Schwanstecher, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_1 · Cited by 13
The Specificity of DP IV for Natural Substrates is Peptide Structure Determined
Kühn‐Wache, K., Hoffmann, T., Manhart, S., Brandt, W., & Demuth, H. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47920-6_6 · Cited by 10
Kadowaki, S., Siraj, M. A., Chen, W., Wang, J., Parker, M., Nagy, A., Fan, C. S., Runeckles, K., Li, J., Kobayashi, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027163 · Cited by 11
Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Hayakawa, M., & Shibasaki, M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0348-x · Cited by 10
“DPP-IV is a serine protease that removes the dipeptides from the N terminus of the substrate peptide by cleaving post proline or alanine residues, and exists as both a membrane-bound protein in several tissues and as a soluble protein in plasma (Mentlein 1999).”
BackgroundInfluentialSTOLAR, M. W., Chen, S., & Grimm, M. F. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48837 · Cited by 12
“The dipeptidyl peptidase 4 (DPP-4) inhibitors increase the levels of native GLP-1 by a different mechanism, ie, by inhibiting DPP-4, a widely dispersed and promiscuous protease that normally turns over native GLP-1 rapidly in vivo.(19) Administered orally, currently available DPP-4 inhibitors include sitagliptin,(20)…”
Rydgren, T., Börjesson, A., Carlsson, A., & Sandler, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.011 · Cited by 10
Mongongu, C., Coudoré, F., Domergue, V., Ericsson, M., Buisson, C., & Marchand, A. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3016 · Cited by 11
Therapy for Obesity Based on Gastrointestinal Hormones
Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.339 · Cited by 13
Exenatide and feeding: Possible peripheral neuronal pathways
Hunt, J. V., Washington, M. C., & Sayegh, A. I. (2011) · Peptides · doi:10.1016/j.peptides.2011.12.009 · Cited by 12
Liu, R., Li, Y., Ren-min, H., Jin, T., Deng, S., Wang, L., Zhang, N., Chen, J., Prud’homme, G. J., Jia, W. W.-G., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.131 · Cited by 11
Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle
ThanThan, S., Saito, T., Yannaing, S., Zhao, H., Nakashima, K., & Kuwayama, H. (2011) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2011.11.004 · Cited by 13
Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice
Riedel, M. J., Lee, C. W. K., & Kieffer, T. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90768.2008 · Cited by 11
Boyle, P. J., & Freeman, J. S. (2007) · PubMed · Cited by 13
Chen, J., Bai, G., Cao, Y., Gao, Z., ZHANG, Q., Zhu, Y., & Yang, W. (2007) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.70190 · Cited by 10
Incretin hormone receptors are required for normal beta cell development and function in female mice
Omar, B. A., Ahlkvist, L., Yamada, Y., Seino, Y., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.03.012 · Cited by 9
Structural Chemistry and Molecular Modeling in the Design of DPP4 Inhibitors
Scapin, G. (2015) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-94-017-9719-1_5 · Cited by 11
The Concentrations of Some Gut Polypeptides Are Elevated During Lactation in Ruminants
Faulkner, A., & Martin, P. A. (1997) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/s0305-0491(97)00227-7 · Cited by 12
Demuth, H., Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00753-2 · Cited by 11
“own papers [19,20], but not Kieffer et al.”
Rachpirom, M., Ovatlarnporn, C., Thengyai, S., Sontimuang, C., & Puttarak, P. (2016) · Walailak Journal of Science and Technology (WJST) · Cited by 11
Improved Human Islet Preparations Using Glucocorticoid and Exendin-4
Miki, A., Ricordi, C., Yamamoto, T., Sakuma, Y., Misawa, R., Mita, A., Inverardi, L., Alejandro, R., & Ichii, H. (2014) · Pancreas · doi:10.1097/mpa.0000000000000184 · Cited by 10
“However, the half-life of GLP-1 is less than 2 minutes owing to rapid inactivation by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4, which make it difficult to use for clinical application.(36) Exendin-4 is a GLP-1 analog that can bind and activate GLP-1 receptor with the same potency as GLP-1.”
BackgroundAdjunctive Sitagliptin Therapy in Postoperative Cardiac Surgery Patients: A Pilot Study
Brackbill, M. L., Rahman, A., Sandy, J. S., Stam, M. D., & Harralson, A. F. (2012) · International Journal of Endocrinology · doi:10.1155/2012/810926 · Cited by 9
“Hindawi Publishing Corporation International Journal of Endocrinology Volume 2012, Article ID 810926, 6 pages doi:10.1155/2012/810926”
BackgroundInfluentialEkholm, E., Shaat, N., & Holst, J. J. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0312-y · Cited by 13
“Total GLP-1 was analyzed as thoroughly explained elsewhere [10].”
MethodSelf-citationSaxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes
Lam, S., & Saad, M. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181daad5f · Cited by 9
“It inactivates the incretins almost immediately following secretion, shortening the half-life of GLP-1 to 2 minutes, and to 5 to 7 minutes for GIP.5,12,13 Saxagliptin is a novel, selective and reversible inhibitor of DPP-4 that leads to elevated levels of endogenous uncleaved, From the *Department of Clinical Pharmacy…”
Background
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.